People with diabetes on semaglutide, in Wegovy and Ozempic, four times more likely to be diagnosed with naion eye disorder
People who have been prescribed a weight-loss injection could be at a higher risk of developing an eye condition which can lead to blindness, a study has found.
The study found that people with diabetes who were prescribed semaglutide, most commonly known under the brand names Wegovy and Ozempic, were over four times more likely to be diagnosed with an eye condition known as non-arteritic anterior ischemic optic neuropathy (naion).
About Author
More Stories
Memo to Trump: US telecoms is vulnerable to hackers. Please hang up and try again | John Naughton
Bizarre Australian mole even more unusual than first thought, new research reveals
Male mosquitoes to be genetically engineered to poison females with semen in Australian research